一般演題１４

[O14-5] QUASAR長期継続試験の92週までの潰瘍性大腸炎に対するグセルクマブの有効性および安全性

*久松 理一¹、Gary R. Lichtenstein²、Jessica R. Allegretti³、David T Rubin⁴、Brian G. Feagan⁵、Brian Bressler⁶、Julián Panés⁷、Waqqas Afif⁸、Mark A Samaan⁹、Byong Duk Ye¹⁰、Shadi Yarandi¹¹、Matthew Germinaro¹¹、Nicole Shipitofsky¹¹、Ye Miao¹¹、Pankaj Mistry¹¹、Hongyan Zhang¹¹、吉越 真一¹²、佐々木 絢子¹²、Axel Dignass¹³、Bruce E. Sands¹⁴、Laurent Peyrin-Biroulet¹⁵ (1. 杏林大学医学部 消化器内科学、2. University of Pennsylvania、3. Division of Gastroenterology, Hepatology and Endoscopy, Brigham and Women’s Hospital, Harvard Medical School、4. University of Chicago Medicine Inflammatory Bowel Disease Centre、5. Western University、6. University of British Columbia、7. Hospital Clínic de Barcelona, IDIBAPS, CIBERehd、8. Division of Gastroenterology, McGill University Health Care、9. Inflammatory Bowel Disease Unit, Guy’s and St Thomas’ NHS Foundation Trust、10. University of Ulsan College of Medicine, Asan Medical Cente、11. Janssen Research & Development, LLC、12. Johnson & Johnson、13. Department of Medicine I, Agaplesion Markus Hospital, Goethe University、14. Icahn School of Medicine at Mount Sinai、15. University of Lorraine, Inserm, NGERE and Groupe Hospitalier Privé Ambroise Paré-Hartmann, Paris IBD Centre)